TY - JOUR
T1 - The role of gadolinium-based contrast agents in magnetic resonance imaging structured reporting and data systems (RADS)
AU - Parillo, Marco
AU - Mallio, Carlo Augusto
AU - van der Molen, Aart J.
AU - Rovira, Àlex
AU - Dekkers, Ilona A.
AU - Karst, Uwe
AU - Stroomberg, Gerard
AU - Clement, Olivier
AU - Gianolio, Eliana
AU - Nederveen, Aart J.
AU - Radbruch, Alexander
AU - Quattrocchi, Carlo Cosimo
N1 - Funding Information: The ESMRMB-GREC (Gadolinium Research and Education Committee) is a group of multidisciplinary ESMRMB members, including academic experts of industries. GREC annual meetings are sponsored by the unconditional support of Bayer AG, Bracco, GE Healthcare, and Guerbet. Funding Information: Open access funding provided by Università degli Studi di Trento within the CRUI-CARE Agreement. The authors did not receive support from any organization for the submitted work. Publisher Copyright: © 2023, The Author(s).
PY - 2023
Y1 - 2023
N2 - Among the 28 reporting and data systems (RADS) available in the literature, we identified 15 RADS that can be used in Magnetic Resonance Imaging (MRI). Performing examinations without using gadolinium-based contrast agents (GBCA) has benefits, but GBCA administration is often required to achieve an early and accurate diagnosis. The aim of the present review is to summarize the current role of GBCA in MRI RADS. This overview suggests that GBCA are today required in most of the current RADS and are expected to be used in most MRIs performed in patients with cancer. Dynamic contrast enhancement is required for correct scores calculation in PI-RADS and VI-RADS, although scientific evidence may lead in the future to avoid the GBCA administration in these two RADS. In Bone-RADS, contrast enhancement can be required to classify an aggressive lesion. In RADS scoring on whole body-MRI datasets (MET-RADS-P, MY-RADS and ONCO-RADS), in NS-RADS and in Node-RADS, GBCA administration is optional thanks to the intrinsic high contrast resolution of MRI. Future studies are needed to evaluate the impact of the high T1 relaxivity GBCA on the assignment of RADS scores.
AB - Among the 28 reporting and data systems (RADS) available in the literature, we identified 15 RADS that can be used in Magnetic Resonance Imaging (MRI). Performing examinations without using gadolinium-based contrast agents (GBCA) has benefits, but GBCA administration is often required to achieve an early and accurate diagnosis. The aim of the present review is to summarize the current role of GBCA in MRI RADS. This overview suggests that GBCA are today required in most of the current RADS and are expected to be used in most MRIs performed in patients with cancer. Dynamic contrast enhancement is required for correct scores calculation in PI-RADS and VI-RADS, although scientific evidence may lead in the future to avoid the GBCA administration in these two RADS. In Bone-RADS, contrast enhancement can be required to classify an aggressive lesion. In RADS scoring on whole body-MRI datasets (MET-RADS-P, MY-RADS and ONCO-RADS), in NS-RADS and in Node-RADS, GBCA administration is optional thanks to the intrinsic high contrast resolution of MRI. Future studies are needed to evaluate the impact of the high T1 relaxivity GBCA on the assignment of RADS scores.
KW - Contrast media
KW - Gadolinium
KW - MRI
KW - RADS
KW - Reporting and data systems
UR - http://www.scopus.com/inward/record.url?scp=85171163625&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s10334-023-01113-y
DO - https://doi.org/10.1007/s10334-023-01113-y
M3 - Review article
C2 - 37702845
SN - 0968-5243
JO - Magma (New York, N.Y.)
JF - Magma (New York, N.Y.)
ER -